BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

immatics biotechnologies GmbH to Present at CIMT Annual Meeting 2013 in Mainz, Germany


5/13/2013 10:16:12 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Tuebingen, 13. May 2013 - immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announces today that the Company will make a number of presentations on its therapeutic cancer vaccine research at the Association for Cancer Immunotherapy (CIMT) Annual Meeting 2013 (14-16 May) in Mainz, Germany. CIMT is Europe’s largest meeting focused on cancer immunotherapy research and development.

Details of the presentations are as follow:

Session: CIP Breakout Workshop

Type: Talk

Presentation title: MDSC update

Date: Tuesday, 14 May, 3pm – 5pm CET

Presenter: Steffen Walter, immatics biotechnologies GmbH, Germany

Location: Hall C

Session: Short Talk Session III / Immunomonitoring

Type: Talk

Presentation title: A novel clinically validated method to predict T-cell epitope immunogenicity for cancer vaccine development

Date: Wednesday, 15 May, 11.15am – 11.30am CET

Abstract number: 056

Presenter: Sarah Kutscher, immatics biotechnologies GmbH, Germany

Location: Hall C

Session: Plenary Session 6 / Regulatory Research

Type: Talk

Presentation title: Immunomonitoring regulation – A user’s perspective

Date: Thursday, 16 May, 11.20am – 11.45am

Presenter: Steffen Walter, immatics biotechnologies, CIMT-CIP (Tuebingen, Germany)

Session Chair: Harpreet Singh (immatics, Tuebingen, Germany), Cedrik Britten (Ribological, Mainz, Germany)

Location: Hall A

In addition, immatics will make poster presentations, as follow:

Tuesday, 14 May, 3pm – 5.30pm

Wednesday, 15 May, 4pm – 5.30pm

Abstract number: 56

A novel clinically validated method to predict T-cell epitope immunogenicity for cancer vaccine development Abstract number: 169

Two alternative variants from human hydin are cancer-associated antigens

Abstract number: 215

The Glioma Actively Personalized Vaccine Consortium (GAPVAC)

For additional information on immatics please visit www.immatics.com or contact:

Paul Higham, CEO

Dr. Nikola Wiegeler, Assistant to the Management

immatics biotechnologies GmbH

Phone: +49 7071 5397 110

E-mail: media@immatics.com

Citigate Dewe Rogerson

David Dible / Chris Gardner / Sita Shah

Phone: +44 207 638 9571

E-mail: david.dible@citigatedr.co.uk

About immatics

immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.

immatics’ unique technology platform XPRESIDENTTM discovers novel relevant cancer antigens known to be expressed on tumor cells, tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast to widely used existing in silico and indirect methods to identify peptide antigens immatics’ TUMAPs are confirmed to be naturally expressed in primary cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells) against tumor cells.

immatics’ vaccines contain multiple TUMAPs to maximize the chances of clinical success by increasing the number of targets on cancer cells that they address. Phase 2 results with IMA901 and IMA910 have shown significantly better survival in patients who respond to multiple TUMAPs in both of these vaccines.

immatics’ multi-peptide vaccines are ‘drug like’, i.e. fully synthetic, off-the-shelf, easily scalable and stable. immatics is based in Tuebingen and Martinsried (Munich), Germany.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES